Search Patents
  • ENGINEERING CORONAVIRUS SPIKE PROTEINS AS VACCINE ANTIGENS, THEIR DESIGN AND USES
    Publication number: 20230226170
    Abstract: A vaccine for preventing CoV infection includes at least one DNA, RNA or protein sequence for S protein with at least one modification which is a full deletion or partial deletion of the SI region or a partial or full replacement of the SI region. A method of vaccinating a mammal subject against infection from at least one group of CoV includes separating a broad group of CoV into homology groups, creating a modified S protein containing at least one modification at its S1 region, and identifying at least one consensus sequence for each homology group which has a sequence identity of greater than 60% to all other members of the homology group. The consensus sequence is a protein sequence for the modified S protein, a DNA sequence encoding the modified S protein, and an RNA sequence encoding the modified S protein.
    Type: Application
    Filed: May 12, 2021
    Publication date: July 20, 2023
    Inventors: Uwe D. STAERZ, Daniel F. PRESTON, Yan QI
  • ANTI-SARS CORONAVIRUS-2 SPIKE PROTEIN ANTIBODIES
    Publication number: 20230295274
    Abstract: Provided are antibodies or antigen binding fragments that specifically recognize a SARS-CoV-2 S protein.
    Type: Application
    Filed: July 27, 2021
    Publication date: September 21, 2023
    Applicant: Single Cell Technology, Inc.
    Inventors: Leyan Tang, Allison Schulkins, Kimberly Than, Chun-Nan Chen
  • Purified trimeric S protein as vaccine against severe acute respiratory syndrome virus infections
    Publication number: 20070003577
    Abstract: Immunogenic compositions and vaccines associated with the Spike protein of SARS Corona Virus (SARS CoV) are disclosed.
    Type: Application
    Filed: June 27, 2006
    Publication date: January 4, 2007
    Inventors: Yiu Kam, Francois Kien, Kid Chu, Anjeanette Roberts, Kanta Subbarao
  • RECOMBINANT PROTEIN AND VACCINE COMPOSITION OF PORCINE EPIDEMIC DIARRHEA VIRUS
    Publication number: 20220370597
    Abstract: A recombinant protein and a vaccine composition for porcine epidemic diarrhea (PED) are provided. The recombinant protein is a fusion protein formed by connecting the truncated segment of S protein (Spike protein) from porcine epidemic diarrhea virus (PEDV) in tandem with the Fc fragment of porcine IgG, and the truncated fragment of S protein is preferably selected from N-terminal domain (NTD) with sialic acid binding activity in S1 subunit of S protein, neutralizing epitope domain (COE) and multiple B-cell epitopes in S2 subunit; the vaccine composition contains recombinant protein and adjuvants. The recombinant protein of the application can produce IgG antibody and neutralizing antibody titers of rather high level after immunizing mice, and the proportions of CD3+CD4+, CD3+CD8+ lymphocytes and the concentrations of IFN-? and IL-4 in lymphocytes are significantly increased.
    Type: Application
    Filed: January 27, 2022
    Publication date: November 24, 2022
    Inventors: Bin Li, Baochao Fan, Danyi Shi, Jinzhu Zhou, Rongli Guo, Kongwang He, Yongxiang Zhao, Xuejiao Zhu, Li Li, Wei Wang, Dandan Wang, Haodan Zhu
  • ANTIBODIES TO CORONAVIRUS SPIKE PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20230399384
    Abstract: Provided herein are antibodies binding to Coronavirus S protein and the uses of the antibodies in detecting and treating Coronavirus infection, such as COVID-19.
    Type: Application
    Filed: April 22, 2021
    Publication date: December 14, 2023
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhiqiang KU, Ningyan ZHANG, Zhiqiang AN, Xuping XIE, Pei-Yong SHI
  • Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
    Publication number: 20230348569
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Application
    Filed: June 29, 2023
    Publication date: November 2, 2023
    Inventors: Robert BABB, Alina BAUM, Gang CHEN, Cindy GERSON, Johanna HANSEN, Tammy HUANG, Christos KYRATSOUS, Wen-Yi LEE, Marine MALBEC, Andrew MURPHY, William OLSON, Neil STAHL, George D. YANCOPOULOS
  • Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence
    Patent number: 11684668
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: June 27, 2023
    Assignee: NantCell, Inc.
    Inventor: Kayvan Niazi
  • Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
    Publication number: 20220356230
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Application
    Filed: March 19, 2021
    Publication date: November 10, 2022
    Inventors: Robert Babb, Alina BAUM, Gang CHEN, Cindy GERSON, Johanna HANSEN, Tammy HUANG, Christos KYRATSOUS, Wen-Yi LEE, Marine MALBEC, Andrew MURPHY, William OLSON, Neil STAHL, George D. YANCOPOULOS
  • bacteriophage tailspike protein and uses thereof
    Patent number: 9063141
    Abstract: The present invention relates to a novel tail spike protein (TSP) encoded by the novel Listeria bacteriophage designated ProCC P825 and uses of the novel TSP for identifying, detecting and monitoring of Listeria.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: June 23, 2015
    Assignee: BIOMERIEUX SA
    Inventors: Holger Grallert, Sonja Molinaro, Julia Lorenz
  • ANTI COVID-19 THERAPIES USING CD40 LIGAND FUSION PROTEIN
    Publication number: 20210284713
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a extracellular portion of CD40 ligand (CD40L) coupled by a flexible linker to a coronavirus 2 (CoV2) spike protein and/or a CoV2 nucleocapsid protein.
    Type: Application
    Filed: October 28, 2020
    Publication date: September 16, 2021
    Inventors: Kayvan Niazi, Jay Gardner Nelson, Annie Shin, Clifford Anders Olson, Shiho Tanaka
  • FUSION PROTEIN AND APPLICATION THEREOF
    Publication number: 20230416309
    Abstract: The present application relates to one or more fusion proteins, comprising a structural domain of SARS-CoV-2 S(Spike) protein. The present application also relates to an immunogenic composition comprising the fusion protein and an application thereof.
    Type: Application
    Filed: October 22, 2021
    Publication date: December 28, 2023
    Applicants: JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION (PUBLIC HEALTH RESEARCH INSTITUTE OF JI, JIANGSU RECBIO TECHNOLOGY CO., LTD., BEIJING ABZYMO BIOSCIENCES CO., LTD.
    Inventors: Fengcai ZHU, Jiaping YU, Wenrong YAO, Chuxiao YUAN, Shuang WU, Yanyan ZHANG, Yingsong HU, Xiling GUO, Ling ZHANG, Li XIA, Li ZHANG, Jingxin LI, Hongxing PAN, Jianping CHEN, Yong LIU
  • PHOSPHATE-REGULATED EXPRESSION OF BIOLOGICALLY ACTIVE RECOMBINANT CORONAVIRUS GLYCOPROTEINS AND OTHER RECOMBINANT PROTEINS IN PHAEODACTYLUM TRICORNUTUM
    Publication number: 20230322866
    Abstract: Phosphate-regulated expression of recombinant glycoprotein antigens and other recombinant proteins in diatoms is described herein. More specifically, described herein is the expression and purification of glycosylated, immunogenic, and serologically active receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, as well as SARS-CoV-2 nucleocapsid protein, in the marine pennate diatom Phaeodactylum tricornutum, as well as a functional lateral flow assay-based diagnostic device based on the produced recombinant RBD and nucleocapsid protein. Also described herein is the use of phosphate/iron levels in culture media to regulate expression/secretion of recombinant proteins under control of an HASP1 promoter in P. tricornutum or other suitable host cells. Also described herein is a method for increasing the expression/secretion of a recombinant protein by engineering the recombinant protein to lack a Tobacco Etch Virus (TEV) protease cleavage site.
    Type: Application
    Filed: August 30, 2022
    Publication date: October 12, 2023
    Inventors: Samuel S. Slattery, Daniel J. Giguere, Martin Flatley, Gregory B. Gloor, David R. Edgell
  • DENDRITIC HUMAN UNIVERSAL NON-ANTIGEN EDUCAP VACCINE
    Publication number: 20220016163
    Abstract: A non-antigenic microRNA exosomal vaccination that includes dendritic-derived exosomes resulting from the incubation of dendritic cells with Spike Protein of a COVID-19 virus so that the dendritic cells process the Spike Protein of the COVID-19 virus to enable education of naïve T-cells. The exosomes so-derived are then harvested and encapsulated for delayed release oral capsule delivery to selectively reach intestinal antigen-presenting cells in the terminal ileum for stimulating an acquired immune response to the Spike Protein of the COVID-19 virus.
    Type: Application
    Filed: October 6, 2020
    Publication date: January 20, 2022
    Inventor: William Richard Deagle
  • Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
    Patent number: 10954289
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: March 23, 2021
    Assignee: Regeneren Pharmaceuticals, Inc.
    Inventors: Robert Babb, Alina Baum, Gang Chen, Cindy Gerson, Johanna Hansen, Tammy Huang, Christos Kyratsous, Wen-Yi Lee, Marine Malbec, Andrew Murphy, William Olson, Neil Stahl, George D. Yancopoulos
  • Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
    Patent number: 11732030
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: August 22, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, Alina Baum, Gang Chen, Cindy Gerson, Johanna Hansen, Tammy Huang, Christos Kyratsous, Wen-Yi Lee, Marine Malbec, Andrew Murphy, William Olson, Neil Stahl, George D. Yancopoulos
  • SARS-COV-2 SUBUNIT AND VARIANT VACCINES
    Publication number: 20220372080
    Abstract: The present invention includes an immunogenic protein, constructs, vectors, and methods of making, comprising at least 90% amino acid identity to at least one antigenic peptide selected from: a coronavirus Receptor Binding Domain (RBD), coronavirus a Receptor Binding Motif (RBM) of a coronavirus spike protein, a coronavirus spike protein N-terminus, a nucleocapsid protein, one or more T cell epitopes from a coronavirus spike protein, or one or more T cell epitopes from a coronavirus nucleocapsid protein, or combination thereof. In one example, the at least one antigenic peptide is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the carrier protein or peptide tag.
    Type: Application
    Filed: April 21, 2022
    Publication date: November 24, 2022
    Inventors: Peter Kipp, Brian Berquist, Sreenath Palle
  • Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
    Patent number: 10787501
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: September 29, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, Alina Baum, Gang Chen, Cindy Gerson, Johanna Hansen, Tammy Huang, Christos Kyratsous, Wen-Yi Lee, Marine Malbec, Andrew Murphy, William Olson, Neil Stahl, George D. Yancopoulos
  • Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments
    Patent number: 10975139
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 13, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, Alina Baum, Gang Chen, Cindy Gerson, Johanna Hansen, Tammy Huang, Christos Kyratsous, Wen-Yi Lee, Marine Malbec, Andrew Murphy, William Olson, Neil Stahl, George D. Yancopoulos
  • ANTI COVID-19 THERAPIES USING NUCLEOCAPSID AND SPIKE PROTEINS
    Publication number: 20220016234
    Abstract: Disclosed herein are methods for inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in a patient in need thereof. The method comprises administering a vaccine composition comprising a self-adjuvanted SARS-CoV2 Spike (S) RNA-based vaccine (AAHI-SC2), followed by administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion.
    Type: Application
    Filed: August 18, 2021
    Publication date: January 20, 2022
    Inventors: Adrian Rice, Mohit Verma
  • MONOCLONAL ANTIBODIES AGAINST CORONAVIRUSES AND USES THEREOF
    Publication number: 20240101645
    Abstract: The present disclosure is directed to monoclonal antibodies, or antigen-binding fragments thereof, that bind to coronavirus spike proteins, including the spike protein of SARS-CoV-2. These antibodies demonstrate high affinity binding to epitopes on the coronavirus spike protein and/or broad cross-reactivity to the spike protein of various coronaviruses. Compositions comprising the anti-coronavirus antibodies, nucleic acids encoding for the antibodies, recombinant expression vectors, and host cells are also disclosed. The present disclosure is also directed to methods of diagnosing, preventing or treating coronavirus infections, including infections or disease caused by SARS-CoV-2.
    Type: Application
    Filed: January 24, 2022
    Publication date: March 28, 2024
    Inventors: Shelly KREBS, Kayvon MODJARRAD, Nelson MICHAEL, Vincent DUSSUPT, Gina C. DONOFRIO, Samantha TOWNSLEY
Narrow Results

Filter by US Classification